This study determined the effects of high-dose chemotherapy (HDCT) with autologous blood stem cell transplantation (ASCT) on quality of life (QL) in women with metastatic breast cancer prior to, and during treatment, and up to 1-year post-ASCT. Thirty-three women diagnosed with metastatic breast cancer participated in a phase 1 clinical trial of a new combination of cyclophosphamide (CTX) and mitoxantrone (MXT), with dose escalation of paclitaxel. Longitudinal QL data were collected using the functional living index-cancer (FLIC) and symptom scales at seven time periods: pre-induction chemotherapy (CT), post-induction CT, post-high dose CT (HDCT), and at 3, 6, 9 and 12 months post-ASCT. FLIC scores indicated that the worst problems for patients were feelings of hardship on themselves and their families, followed by psychological functioning and physical functioning problems. The time around diagnosis of the metastatic disease and following HDCT were the worst times for all levels of quality of life, but anxiety and depression symptoms continued to increase in severity across the entire follow-up period. The symptoms that were most problematic were worry about the future, loss of sexual interest, anxiety about the treatment, general worrying, and joint pain. These data highlight the problems that women with metastatic breast cancer encounter at different stages of the disease and treatment process, and can be used to tailor psychosocial interventions appropriate for treating the relevant issues at different points in time. Bone Marrow Transplantation (2001) 27, 989-998.
pain. QL problems such as distress are common in cancer patients, 1 and can lead to complications in terms of compliance with treatment regimens and outcome. 2 Indeed, as research has accumulated documenting the prognostic effects of aspects of QL on medical outcomes, [2] [3] [4] measurement of QL has become a bioethical imperative as an endpoint in clinical trials, [5] [6] [7] [8] [9] resulting in a shift from the traditional focus in oncology on tumor response or progression-free survival. 10, 11 Oncologists, as well as clinical nurses and psychosocial staff, are in agreement that QL is an important variable to consider in the treatment of cancer patients, and is increasingly considered a 'hard' endpoint in clinical studies. [12] [13] [14] The phase I clinical trial from which these data were collected 15 was designed to evaluate the dose-limiting toxicity, maximum tolerated dose and efficacy of a new combination of cyclophosphamide (CTX) and mitoxantrone (MXT), with dose escalation of paclitaxel. This was followed by autologous blood stem cell transplant (ASCT). QL data were collected at several time periods both prior to high-dose chemotherapy (HDCT) and at 3-month intervals after treatment, until the patient died or could no longer complete the questionnaires, or until the completion of the study at 2 years post-transplant. Data reported in this paper cover the first year post-transplant, as not enough patients provided follow-up data through the full 2-year follow-up period.
Although there is a growing amount of research investigating the psychosocial experience and quality of life of patients undergoing allogenic bone marrow transplant, 16, 17 very little is known about the experience of those dealing with autologous blood or marrow stem cell transplant. Particularly lacking is investigation of breast cancer patients during ASCT, as this procedure has only recently become commonly utilized in this patient population. 18 Studies that are specific to breast cancer are either entirely retrospective in nature [19] [20] [21] [22] and often include only one assessment time, 19, 21, 23 or, if more than one assessment was conducted, the time span has been limited to less than 1 year post-transplant. 24, 26 As well, the tools used to measure QL are often non-standardized and lack information on validity and reliability. [26] [27] [28] Finally, usually only the experience of long-term survivors is described, which is obviously a necessary limitation of retrospective studies. However, even in prospective studies, those who die before the allotted follow-up period are generally excluded from the analysis at all time periods. 24, 27, 29 The experience and QL of those who do not survive the process long enough to complete the entire study, however, is of interest as well.
Methodological problems notwithstanding, several areas have consistently been described as problematic in women undergoing HDCT/ASCT for the treatment of breast cancer. Sexuality and problems with fertility are common in long-term follow-up studies, 21, 22, 24 not only in breast cancer patients but after ASCT in other populations as well, 26, 30 with as many as half of the patients surveyed reporting significant decreases in sexual interest, activity, pleasure and ability. 21, 30 Some have described poor coping skills, 23 and mood disturbance 25, 28 in breast cancer patients near the time of ASCT, but even at almost 1 year post-ASCT, approximately 30% of the women in one sample had problems with mood and sexuality severe enough to warrant psychosocial intervention. 24 In the shorter term, fatigue has also been prospectively identified as a significant factor affecting the QL of breast cancer patients who had recently undergone ASCT. 31 Thus, well-designed, prospective psychosocial studies of QL in women undergoing ASCT for the treatment of breast cancer are needed, which was the goal of this research. It is hoped that by understanding the needs of this population of patients, better psychosocial interventions can be developed that target the issues most relevant to patients at the appropriate time periods during the illness.
Materials and methods

Patients
Eligibility criteria for inclusion in the trial included women between 18-55 years of age; measurable or evaluable metastatic breast cancer; no previous chemotherapy for metastatic disease; adjuvant chemotherapy, if received, completed at least 6 months prior to first diagnosis of metastatic disease; Karnofsky performance status 60% or greater; and normal cardiopulmonary, liver, kidney and haemotopoietic function. The study was approved by the institutional ethics review board and all patients gave informed consent.
Measures
The Functional Living Index -Cancer (FLIC): A 22-item cancer-specific measure of QL. Items are scored on a continuous visual analogue scale divided into seven increments and labeled with the numbers 1 to 7. The FLIC was designed for easy, repeated patient self-administration, and shows high levels of reliability and validity. 32 The total score on the items is used to represent global quality of life, with higher scores representing a better QL. Scores can range from 22-154. Scores are also calculated on five subscales: physical ability and well-being (nine items), psychological well-being (six items), hardship due to cancer (three items, assessing personal hardship, family hardship and disruption to others), and nausea (two items). This instrument has been used with breast cancer populations in the past, 20, 22, 33 although these studies have reported only the global score.
Symptom scale: A 24-item visual analogue scale designed for this study, which assessed the degree of specific symptomatology, was also administered to all patients. Each item on this scale was also divided into seven increments, and scored in the same manner as the FLIC (all scores were on a scale from 1 (not at all present) to 7 (a great deal present)), with higher scores, in this case, indicating more symptomatology. A total symptom score was calculated by summing all 24 items. Thus, in contrast to the FLIC, higher overall total scores indicate more symptomatology and poorer overall function. Questions assessed symptoms of coughing, dyspnoea, appetite loss, sexual interest, fatigue, fever, abdominal or joint pain, headaches, eye trouble, worry, anxiety, depression, history of alcohol abuse or mental health problems, and financial concerns.
Procedures
Medical procedures are fully detailed elsewhere. 15 All patients supplied informed consent for participation in the trial, and the protocol was fully approved by the institutional ethics review board. To summarize the procedures, the women who met the eligibility criteria received initial induction chemotherapy of 5-flurouracil 2 ) all administered i.v. on day 1, followed on day 4 by recombinant human granulocyte colony-stimulating factor (rhG-CSF; 10 g/kg) daily for 10-11 days. Apheresis was performed to collect stem cells on the day when the white blood cell count reached 2.5/ml or more after a haematologic nadir, and on consecutive days until the target volume of stem cells was collected, at which point the cells were cryopreserved until the time of transplantation. After this first cycle of chemotherapy, a further two (or three cycles in three patients) cycles were administered at 3-week intervals with slightly lower drug doses (5-FU 600 mg/m 2 , EPI 60 mg/m 2 , CTX 600 mg/m 2 ). After induction chemotherapy, all patients were restaged with a physical examination, imaging studies and blood tests.
Patients who did not progress on induction chemotherapy and did not experience severe toxicity and/or major organ damage, proceeded to high-dose chemotherapy administered over 4 days in the inpatient unit. A cumulative dose of CTX 6 g/m 2 and MXT 70 mg/m 2 was administered i.v. over 3 days, and on the 4th day the paclitaxel dose was given. Patients were assigned to one of seven dosage levels of paclitaxel: 250, 300, 350, or 400 mg/m 2 in 3-h i.v. infusions, or 350, 400 or 450 mg/m 2 in 6-h i.v. infusions. Patients were usually discharged from hospital for outpatient observation on the day after the completion of HDCT. After 48 h of rest, the previously collected stem cells were reinfused and rhG-CSF (5 g/kg) was administered s.c. daily until haematological recovery.
The FLIC and symptom scales were first administered at baseline when patients were enrolled in the study, prior to induction chemotherapy (time 1, pre-induction). Patients completed the self-report questionnaires on their own with a research assistant present to answer any questions. The questionnaires were readministered approximately 3 months later, after induction chemotherapy but prior to HDCT (time 2, pre-HDCT). The third administration was a further 2 months later, after HDCT and ASCT (time 3, post-HDCT/ASCT), and every 3 months thereafter to a maximum time of 2-years post-ASCT (times 4-11, at 3, 6, 9, 12, 15, 18, 21, and 24 months). After the patient was discharged, subsequent questionnaires were mailed out with stamped return envelopes. Thus, for a patient followed for the full duration of the study, the QL data will have been collected a total of 11 times over a 2.-year period.
Statistical analysis
Because of the small numbers of patients available for follow-up after 1 year, data for quantitative analysis were cut off after assessment time 7, which was 1 year post-HDCT/ASCT, to allow for analysis. Thus, all analyses were performed on the data up to assessment number seven. To compare the mean FLIC scores obtained by all women who completed questionnaires at each test time, one way ANOVA procedures across time with least significant differences post-hoc t-tests were conducted for each FLIC subscale, the FLIC total score and the symptom total score. These tests compared the means obtained on each subscale across the seven time periods. Because the possible range of scores on each FLIC subscale was different, due to different numbers of questions loading on each subscale, it was difficult to directly compare the raw scores on the different scales to determine the relative importance of the different QL dimensions. Therefore, a standard score out of 7 was calculated for each subscale by dividing the total score by the number of items on the scale, to allow for direct comparisons between the subscales, with higher scores indicating better functioning. The scaled scores were then compared between the subscales at each test time using one-sample t-tests, which allowed us to determine which areas of QL were most problematic for the women at each time period. The same analyses were conducted for the symptom scales.
Results
Patients
Between November 1994 and October 1996, 50 female patients with metastatic (M1) breast cancer were enrolled. Forty patients who did not progress on induction chemotherapy, were eligible to be treated with HDCT. The median age was 46 years (range 29-55 years). Before developing metastatic disease, seven patients (17.5%) were diagnosed with stage I, 22 patients (55%) with stage II, three patients (7.5%) with stage III breast cancer, and eight patients (20%) presented initially M1 disease. Twenty-three patients (57.5%) were premenopausal and 13 (32.5%) had hormone receptor negative tumors. Twenty-two patients (55%) received adjuvant chemotherapy and eight (20%) of them received an anthracycline-containing regimen. Only 13 (32.5%) had adjuvant tamoxifen. Six patients (15%) had bone only metastases, and 21 (52.5%) patients had metastatic disease involving tissue other than liver or lung. Sixteen (40%) had lung and eight (20%) had liver metastasis. Approximately one third of our patients had three or more sites involved, representing a poor prognosis population.
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Forty-three of these patients completed QL information at time 1 (prior to HDCT) and 42 at time 2. The quality of life component was added after the start of the protocol, so the first seven patients were not included. Of the original 50, 40 did not progress on induction chemotherapy and were eligible for HDCT and ASCT, of which 33 provided QL data. The numbers and ages of patients who provided QL data at each time point are presented in Table 1 . Because of the small numbers of patients available for follow-up after 1 year, data were cut off after assessment time 7 at 1 year post-HDCT/ASCT. Thus, all data analyses were performed on the data up to and including assessment number seven. All women provided data for each consecutive assessment until the point at which they dropped out, with the exception of two women, one of whom provided data at points 1, 2, 3, and 5, and another who provided data at points 1, 2, 3, 4, 5, and 7. All available data from each timepoint were analyzed cross-sectionally to maximize the power of each comparison.
FLIC
FLIC scores were analyzed using one-way ANOVA to compare each of the subscale scores and the total score over the seven test times. Overall significant differences were found on the Physical well-being (F[6,176] = 2.35, P Ͻ 0.05), and Hardship (F[6,176] = 5.99, P Ͻ 0.001) subscales, and nonsignificant trends was seen on the Nausea (F[6,176] = 1.92, P = 0.08) subscale, and on the Total score (F[6,176] = 2.03, P = 0.06). Means and standard deviations are presented in Table 2 , with higher scores representing better functioning. When probed with least significant differences post-hoc tests, on the physical well-being scale, scores at time 1 were less than at time 2 (P Ͻ 0.05) and at times 2 and 5 scores were greater than at time 3 (P Ͻ 0.01). On the hardship subscale, time 1 scores were less than those at times 2, 4, 5, 6 and 7 (P Ͻ 0.001), and scores at time 3 were also less than at times 4, 5 and 7 (P Ͻ 0.05). In terms of nausea, scores at time 3 were lower than at times 1, 4 and 5 (P Ͻ 0.05). For the total score, time 1 scores were lower than those at time 2 (P Ͻ 0.05), and at time 3 scores were lower than at times 2 and 5 (P Ͻ 0.05). When those patients who responded during induction chemotherapy and did not progress to HDCT (n = 9) were compared to those who did not respond (n = 33) at times 1 and 2 using independent samples t-test, the only difference was on the Nausea subscale, with the non-responders feeling more nauseated at time 2 only (t = 2.19, P Ͻ 0.05), after the induction chemotherapy. These results illustrated that physical symptoms on the FLIC were most troublesome at time 1, when first enrolled in the study, and at time 3, after the HDCT/ASCT, as seen on Table 2 and Figure 1 . Hardship due to cancer was most problematic at time 1, became less burdensome before HDCT, but again became problematic at time 3, again after the HDCT/ASCT. Hardships became less of a difficulty after treatment at times 4-7. Nausea, as well, was at its worst at time 3, compared with the intervals prior to treatment and during recovery. Therefore, the total scores reflected the decreased QL at times 1 and 3, with higher overall QL just before HDCT, and after recovery at time 5.
Because the possible range of scores on each subscale is different, due to different numbers of questions loading on each subscale, it is difficult to directly compare the raw scores on the different scales. Therefore, a standard score out of 7 was calculated for each subscale to allow for direct comparisons between the subscales. These are presented graphically in Figure 1 and included in Table 2 . Higher scores indicate better functioning. When the scaled scores were compared between the subscales at each test time using one-sample t-tests, scores on the Social and Nausea subscales overall were higher than those of the Physical, Psychological, and Hardship subscales at each test time (t range = 2.7-34.2: all P Ͻ 0.05), indicating less social and nausea problems overall. The highest scores (indicating the best QL) occurred on the Nausea scale, with scores higher Higher scores indicate better functioning. Nausea scores were higher than Social functioning at times 1 (t = 3.39, P Ͻ 0.01), 4 (t = 4.25, P Ͻ 0.001) and 5 (t = 7.80, P Ͻ 0.001), and higher than Physical, Psychological and Hardship scales at all time periods. Social functioning scores were higher than Physical, Psychological and Hardship scores at all times. Hardship scores were lower than both Psychological and Physical scores at times 1 (t = 7.3, P Ͻ 0.001; t = 8.2, P Ͻ 0.001, respectively) and 3 (t = 3.2, P Ͻ 0.01; t = 3.9, P Ͻ 0.001).
than on Social functioning at times 1 (t = 3.39, P Ͻ 0.01), 4 (t = 4.25, P Ͻ 0.001) and 5 (t = 7.80, P Ͻ 0.001). The next highest scores occurred on the Physical and Psychological scales, which were not significantly different from each other at any test time (but lower than Nausea and Social functioning). Hardship scores were lower than both Psychological and Physical scores at times 1 (t=7.3, P Ͻ 0.001; t = 8.2, P Ͻ 0.001, respectively) and 3 (t = 3.2, P Ͻ 0.01; t = 3.9, P Ͻ 0.001), indicating more Hardship during these time periods.
When groups were evaluated with one-way ANOVA on the FLIC scores based on the dosage of paclitaxel at each of the test times, no significant group differences were found at any test time. This indicates that the dose of paclitaxel did not have an effect on QL at any assessment time.
Because so many women dropped out of data collection after ASCT, we wished to determine if those who dropped out had worse QL initially. Accordingly, subjects who completed six or more assessments were compared to those who completed five or fewer assessments on initial FLIC scores, with independent samples t-tests. No differences were found. The women were then divided at each test time into two groups: those who had relapsed since the previous data collection period or who subsequently relapsed before the next assessment period (within the next 3 months), and those who did not relapse within the next 3 months. The grouping together of those who had just relapsed and those who went on to relapse before the next assessment was due to the very small numbers of women who continued to provide data after a relapse -only three women at the post HDC/ASCT collection period, two women at 6 months post, and one women at 9 months post, all within 1 month of relapse. The two groups were then compared using the total FLIC score and independent samples t-tests, represented in Figure 2 . Women who relapsed showed lower FLIC scores, indicating worse quality of life, at the postinduction (t = 2.1, P Ͻ 0.05), post HDC/ASCT (t = 2.7, P Ͻ 0.05), and 3-month follow-up (t = 2.3, P Ͻ 0.05) time points.
Finally, to get a picture of the course of FLIC scores for the women who provided data at all seven time points (eight women), standardized scores across time were plotted ( Figure 3 ). The pattern of change and the relative levels of each of the subscales were not appreciably different than that seen for the entire sample. Comparing change over time on each of the subscales using one-way ANOVA with least significant differences post-hoc analysis, similar results to the full sample were seen, except that some of the comparisons did not meet statistically significant levels due to the small sample size. As well, when mean scores on each subscale for those with complete data were compared to those of the group that did not provide complete
Bone Marrow Transplantation data at each time point, the only difference was found at time 2, post-induction, on the Hardship subscale. The women who provided complete data reported lower levels hardship at that time than those who did not (t = −2.1, P Ͻ 0.05), but no differences were found on other subscales at any other time.
Symptom scales
Complete data to compute the total symptom score were available for 121 of 183 subject/time pairs, since there were instances in which women may have provided FLIC data but not symptom scale information. On the symptom scale total score, overall no significant differences were seen across time periods (F[6,115] = 1.62, P = 0.15), although the difference between symptoms at times 2 and 3 followed the same pattern as the FLIC scores, with symptoms worse at times 1 and 3 than at time 2. Mean scores across all assessment times for individual symptoms are presented in Table 3 . All scores are on a scale from 1 (not at all present) to 7 (a great deal present). The symptoms that were most troublesome to patients Anxiety was lower at time 2 than at all other test times (all P Ͻ 0.01). At time 2, depression was significantly less than at times 3-7 (all P Ͻ 0.05). At time 3, tiredness was higher than at all other times (all P Ͻ 0.01). Appetite covaried with tiredness, with the most appetite loss at time 3 compared to times 2, 4 and 5 (all P Ͻ 0.05).
cating more symptomatology. At time 2, post-induction chemotherapy, anxiety was lower than all other test times (all P Ͻ 0.01). The most anxiety occurred at times 1 and 7. Depression scores followed a similar pattern, in that the least depressive symptoms occurred at time 2, which was significantly less than the depressive feelings reported at times 3-7 (all P Ͻ 0.05). The highest occurrence of depression symptoms was at time 6, 9 months post-ASCT. The most tiredness occurred at time 3, post HDCT/ASCT, when the patients felt more tired than at all other times (all P Ͻ 0.01). Appetite correlated with tiredness, in that the most problems with appetite occurred at time 3, which was significantly higher than at times 2, 4 and 5 (all P Ͻ 0.05).
Comparing the drop-outs to the non-dropouts, as had been done with FLIC scores, no differences in initial symptom levels were found. When comparing those who relapsed within the next 3 months to those who did not, as described above, no differences were found in overall symptom scores at any assessment period.
Finally, to get a picture of the course of symptom scores for the women who provided data at all seven time points (eight women), their standardized scores across time were plotted ( Figure 5 ). The pattern of change and the relative levels of each of the subscales were not appreciably different than those seen for the entire sample, similar to the case with the FLIC scores. As well, when mean scores on each subscale for those with complete data were compared to those of the group that did not provide complete data at each time point, no differences were found.
Survival
Status and dates of death were obtained for all 33 participants who underwent HDCT/ASCT, as of 1 January 1999. At that point, 22 women had died and 11 were still alive. Survival times were calculated as time between 
Discussion
The results of this study allowed the analysis of the dynamic changes in quality of life during the treatment of patients with metastatic breast cancer undergoing HDCT/ASCT. A pattern of responses was seen, illustrating that the two most difficult times of the process were the time of initial enrollment, when the metastatic disease had been recently diagnosed, and the period immediately after the HDCT/ASCT. When patients had recently been diagnosed with metastatic cancer, anxiety and depressed mood were prominent, and patients felt a great deal of hardship had been placed upon them and their families. This is not surprising as a metastatic diagnosis is very likely to bring about fears of death, dying, and end of life issues. Physically, the most taxing time was post-HDCT/ASCT, when patients felt more nausea, fatigue and appetite loss than at other times, an expected result of the rigorous treatment regimen. This time was also quite taxing psychologically, in that feelings of anxiety and depression increased again at this third assessment time. It is of interest to note that the four most bothersome symptoms to patients across the illness trajectory were psychological, rather than physical; worry about the future, anxiety during treatment, general worry, and decreases in sexual interest. This supports a growing literature indicating that sexuality and fertility issues are prominent problems in women who have undergone ASCT for the treatment of breast cancer. 21, 22, 24, 26, 27, 30 Interestingly, while several studies have reported that QL returns to quite high levels within a year of Bone Marrow Transplantation HDCT/ASCT, 22, 26, 27, 29 in this population of patients with metastatic breast cancer, psychological symptoms of anxiety and depression increased from the time of treatment right through the first year post-treatment. In a sample of lymphoma patients, 1 year after ASCT, role, social, physical and cognitive functioning, as well as overall QL, were impaired relative to a normative healthy sample. 34 The most problematic areas for patients overall in the current study were feelings of hardship and problems in overall psychological functioning. These increases in psychological distress occurred during a time period that was very near the end of life for many of these women. In the palliative care literature, increases in anxiety and depression near the end of life have been reported as quite common in terminally ill patients, 35 and we also saw decreased QL scores in those patients who relapsed within 3 months of assessment compared to those who did not relapse within that time period. Indeed, at all transition points during the illness, distress has been reported as quite a common symptom, with an average of 35% of patients reporting significant distress. 36 Other researchers have also used the FLIC in studies of breast cancer and reported overall total scores. In a group of 62 patients with metastatic breast cancer planning to undergo ASCT, a FLIC total score of 106 (s.d. = 19.7) was reported prior to induction chemotherapy, 37 very similar to our score of 108. Several studies have investigated survivors of HDCT/ASCT at differing time periods after the treatment. An average of 30.6 months after treatment, 82 patients who had been treated for stage II/III or metastatic breast disease reported a mean FLIC score of 130.8 (s.d. = 19.1), 22 higher than our 1-year follow-up score of 117 (s.d. = 18.9). This may be due to the less severe nature of the illness in these women compared to our study of only metastatic and usually terminal illness. Indeed, approximately one-third of our sample did not survive past 12 months post HDCT/ASCT. As such, it is not surprising that the QL scores are lower in this population in which many of the participants were assessed near the end of their lives.
In a large study comparing people across the disease spectrum, FLIC scores of those under terminal care (mean 83.0, s.d. 15.7) were significantly lower than those who had no current therapy (mean 117. 4 36 The scores in our sample were much higher than those of the terminal care patients in the Zabora study, but similar to the curative therapy group immediately after HDCT, and similar to the adjuvant treatment, no treatment, and symptom control groups on follow-up assessments.
The main limitation of this study lies in the small number of women who completed the questionnaires throughout the follow-up. Initially, our response rate was very good, with all eligible patients in the trial providing QL information. By the 1 year post-ASCT point, however, which was 18 months into the protocol, these numbers dropped to 42% of surviving patients. The reasons for not completing data could be numerous, but unfortunately were not investigated in this trial. We did consider the possibility that those who dropped-out of the QL assessment may have had worse initial QL, but their scores were no different from those of the women who completed at least six assessments. Women did tend to discontinue providing QL information following a relapse of the disease, which was often preceded by dropping QL scores. Prospective trials will have to work to decrease attrition over time, perhaps by using more rigorous follow-up procedures.
Since women with metastatic breast cancer are essentially incurable with standard therapy, with a median survival of about 18-24 months after documentation of metastases, 38 and with less than 10% of all patients alive at 5 years, assessment of QL becomes an essential endpoint in measuring treatment outcomes of these patients. HDCT has been investigated in clinical studies for a number of years, but still remains experimental in nature. Although a few studies indicate an advantage of this treatment modality over standard-dose chemotherapy, 39 results of randomized prospective studies remain controversial. In a small sample of women, an event-free survival of 16 vs 27 months, and an overall survival difference of 16 vs 36 months was found for standard treatment vs HDCT, 40 but these results were not statistically significant. A larger study of 199 metastatic breast cancer patients found that event-free survival (6 vs 10 months) and overall survival (24 vs 26 months) did not show any significant advantage of HDCT over standard treatment. 41 Unfortunately, none of the above studies measured QL, so the differential impact of standard treatment vs HDCT on QL is relatively unknown. Until sufficient evidence becomes available concerning the efficacy of HDCT over standard-dose chemotherapy, however, QL remains the most important issue for patients with metastatic breast cancer, and therefore the most important endpoint for clinical trials design. Data from our study clearly show higher QL just before HDCT and after recovering from HDCT/ASCT. At these time points, patients are not only in clinical (partial or complete) remission, or with stable disease, but are also without any active treatment. These data also suggest the comparability of this treatment to other regimens in terms of QL disruption. Nonetheless, to carefully address the impact of different treatment regimens on QL, a formal comparison of QL using HDCT vs standard-dose chemotherapy becomes a crucial part of any phase III study, and is currently an integral part of a large randomized prospective phase III study in Canada (NCI-C MA.16). 42 There is substantial a body of research investigating the effects of psychosocial interventions on various aspects of QL in patients with advanced disease. Spiegel and colleagues, [43] [44] [45] for example, have shown that supportiveexpressive therapy for metastatic breast cancer resulted in less anxiety and depression, as well as improvements in overall quality of life and decreased levels of distress. Other types of group interventions, including cognitive behavioural therapies 46 and mindfulness meditation-based stress reduction 47 have also been shown effective in improving QL in a variety of cancer patient populations, including patients with advanced disease (reviewed in Refs 48, 49) . Thus, there is reason to believe that women similar to those studied in this research would be likely to benefit from psychosocial interventions aimed at improving QL.
In summary, these QL data are consistent with those of other reports in highlighting many areas of concern for women undergoing HDCT/ASCT treatment. The next step will involve using this information to design intervention strategies that address these areas of concern. As well, this knowledge can be used to maximize the timing of interventions to address the issues that are most relevant at different times in the trajectory. For example, our data highlighted the degree to which women feel their illness has caused hardship on their family members. With this in mind, support groups either solely designed for family members, or including both patients and family, may address this concern at relevant points in time. Psychological problems such as anxiety and depression are also present, particularly around the time of diagnosis of metastatic disease, and then again later in the trajectory beyond 6 months post-ASCT. In keeping with this knowledge, short-term interventions targeting pre-ASCT anxiety could be offered, followed later with interventions targeting existential and end-of-life issues, after the crisis period of the HDCT/ASCT has passed. The differential impact on QL of HDCT/ASCT vs standard treatment for metastatic breast cancer has yet to be assessed in clinical trials, an issue that should also be addressed. Whether HDCT/ASCT will ultimately prove superior to standard chemotherapy is not yet known, however, with the addition of this study, the body of knowledge concerning the experience of women undergoing HDCT/ASCT has reached the point where it is imperative to address some of the psychosocial issues uncovered by this exploratory research. In this way, we can hope to help alleviate the burden of suffering in these patients and their family members.
